260 related articles for article (PubMed ID: 20532824)
1. The clinical manifestation of MCAD deficiency: challenges towards adulthood in the screened population.
Schatz UA; Ensenauer R
J Inherit Metab Dis; 2010 Oct; 33(5):513-20. PubMed ID: 20532824
[TBL] [Abstract][Full Text] [Related]
2. Impact of newborn screening for fatty acid oxidation disorders on neurological outcome: A Belgian retrospective and multicentric study.
Everard E; Laeremans H; Boemer F; Marie S; Vincent MF; Dewulf JP; Debray FG; De Laet C; Nassogne MC
Eur J Paediatr Neurol; 2024 Mar; 49():60-65. PubMed ID: 38377647
[TBL] [Abstract][Full Text] [Related]
3. Clinical aspects of short-chain acyl-CoA dehydrogenase deficiency.
van Maldegem BT; Wanders RJ; Wijburg FA
J Inherit Metab Dis; 2010 Oct; 33(5):507-11. PubMed ID: 20429031
[TBL] [Abstract][Full Text] [Related]
4. Mitochondrial fatty acid oxidation disorders: clinical presentation of long-chain fatty acid oxidation defects before and after newborn screening.
Spiekerkoetter U
J Inherit Metab Dis; 2010 Oct; 33(5):527-32. PubMed ID: 20449660
[TBL] [Abstract][Full Text] [Related]
5. Newborn screening for disorders of fatty-acid oxidation: experience and recommendations from an expert meeting.
Lindner M; Hoffmann GF; Matern D
J Inherit Metab Dis; 2010 Oct; 33(5):521-6. PubMed ID: 20373143
[TBL] [Abstract][Full Text] [Related]
6. Clinical and biochemical outcomes of patients with medium-chain acyl-CoA dehydrogenase deficiency.
Anderson DR; Viau K; Botto LD; Pasquali M; Longo N
Mol Genet Metab; 2020 Jan; 129(1):13-19. PubMed ID: 31836396
[TBL] [Abstract][Full Text] [Related]
7. Follow-up of fatty acid β-oxidation disorders in expanded newborn screening era.
Janeiro P; Jotta R; Ramos R; Florindo C; Ventura FV; Vilarinho L; Tavares de Almeida I; Gaspar A
Eur J Pediatr; 2019 Mar; 178(3):387-394. PubMed ID: 30617651
[TBL] [Abstract][Full Text] [Related]
8. Fatty acid oxidation disorders: outcome and long-term prognosis.
Wilcken B
J Inherit Metab Dis; 2010 Oct; 33(5):501-6. PubMed ID: 20049534
[TBL] [Abstract][Full Text] [Related]
9. Clinical and biochemical monitoring of patients with fatty acid oxidation disorders.
Lund AM; Skovby F; Vestergaard H; Christensen M; Christensen E
J Inherit Metab Dis; 2010 Oct; 33(5):495-500. PubMed ID: 20066495
[TBL] [Abstract][Full Text] [Related]
10. 221 newborn-screened neonates with medium-chain acyl-coenzyme A dehydrogenase deficiency: Findings from the Inborn Errors of Metabolism Collaborative.
Bentler K; Zhai S; Elsbecker SA; Arnold GL; Burton BK; Vockley J; Cameron CA; Hiner SJ; Edick MJ; Berry SA;
Mol Genet Metab; 2016 Sep; 119(1-2):75-82. PubMed ID: 27477829
[TBL] [Abstract][Full Text] [Related]
11. Genotype and residual enzyme activity in medium-chain acyl-CoA dehydrogenase (MCAD) deficiency: Are predictions possible?
Tucci S; Wagner C; Grünert SC; Matysiak U; Weinhold N; Klein J; Porta F; Spada M; Bordugo A; Rodella G; Furlan F; Sajeva A; Menni F; Spiekerkoetter U
J Inherit Metab Dis; 2021 Jul; 44(4):916-925. PubMed ID: 33580884
[TBL] [Abstract][Full Text] [Related]
12. The first three years of screening for medium chain acyl-CoA dehydrogenase deficiency (MCADD) by newborn screening ontario.
Kennedy S; Potter BK; Wilson K; Fisher L; Geraghty M; Milburn J; Chakraborty P
BMC Pediatr; 2010 Nov; 10():82. PubMed ID: 21083904
[TBL] [Abstract][Full Text] [Related]
13. Newborn screening by tandem mass spectrometry for medium-chain Acyl-CoA dehydrogenase deficiency: a cost-effectiveness analysis.
Venditti LN; Venditti CP; Berry GT; Kaplan PB; Kaye EM; Glick H; Stanley CA
Pediatrics; 2003 Nov; 112(5):1005-15. PubMed ID: 14595039
[TBL] [Abstract][Full Text] [Related]
14. Adult presentations of medium-chain acyl-CoA dehydrogenase deficiency (MCADD).
Lang TF
J Inherit Metab Dis; 2009 Dec; 32(6):675-683. PubMed ID: 19821147
[TBL] [Abstract][Full Text] [Related]
15. Mitochondrial fatty acid oxidation disorders: pathophysiological studies in mouse models.
Spiekerkoetter U; Wood PA
J Inherit Metab Dis; 2010 Oct; 33(5):539-46. PubMed ID: 20532823
[TBL] [Abstract][Full Text] [Related]
16. Genotype-phenotype correlations: sudden death in an infant with very-long-chain acyl-CoA dehydrogenase deficiency.
Coughlin CR; Ficicioglu C
J Inherit Metab Dis; 2010 Dec; 33 Suppl 3():S129-31. PubMed ID: 20107901
[TBL] [Abstract][Full Text] [Related]
17. Medium-chain acyl-CoA dehydrogenase deficiency in Saudi Arabia: incidence, genotype, and preventive implications.
Al-Hassnan ZN; Imtiaz F; Al-Amoudi M; Rahbeeni Z; Al-Sayed M; Al-Owain M; Al-Zaidan H; Al-Odaib A; Rashed MS
J Inherit Metab Dis; 2010 Dec; 33 Suppl 3():S263-7. PubMed ID: 20567907
[TBL] [Abstract][Full Text] [Related]
18. A nationwide retrospective observational study of population newborn screening for medium-chain acyl-CoA dehydrogenase (MCAD) deficiency in the Netherlands.
Jager EA; Kuijpers MM; Bosch AM; Mulder MF; Gozalbo ER; Visser G; de Vries M; Williams M; Waterham HR; van Spronsen FJ; Schielen PCJI; Derks TGJ
J Inherit Metab Dis; 2019 Sep; 42(5):890-897. PubMed ID: 31012112
[TBL] [Abstract][Full Text] [Related]
19. Outcomes and genotype-phenotype correlations in 52 individuals with VLCAD deficiency diagnosed by NBS and enrolled in the IBEM-IS database.
Pena LD; van Calcar SC; Hansen J; Edick MJ; Walsh Vockley C; Leslie N; Cameron C; Mohsen AW; Berry SA; Arnold GL; Vockley J;
Mol Genet Metab; 2016 Aug; 118(4):272-81. PubMed ID: 27209629
[TBL] [Abstract][Full Text] [Related]
20. Screening of MCAD deficiency in Japan: 16years' experience of enzymatic and genetic evaluation.
Tajima G; Hara K; Tsumura M; Kagawa R; Okada S; Sakura N; Hata I; Shigematsu Y; Kobayashi M
Mol Genet Metab; 2016 Dec; 119(4):322-328. PubMed ID: 27856190
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
